Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of gout.

"Regulatory clearance for us to proceed with our Phase 1 study of RDEA594, within six months from designation as a clinical candidate is a testament to the efficiency of our development organization, and the importance we place on our gout program -- a program we intend to expand with second-generation compounds from our exciting ongoing research in this area," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Earlier this quarter, we initiated a Phase 2a proof-of-concept study of RDEA806, a prodrug of RDEA594, which should allow us to provide an early confirmation of RDEA594's activity in the target population of patients with gout."

This Phase 1, randomized, double-blind, placebo-controlled trial will evaluate the safety, tolerability, pharmacokinetics and uric acid lowering effects of single ascending oral doses of RDEA594 in healthy adult male volunteers.

About Gout

An estimated 3-5 million people in the United States, and approximately 5 million people in the European Union, suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connective tissue of the joints and in the kid
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. ... inoperable solid tumor cancers, announced today that CEO Linda ... Phacilitate Immunotherapy Forum in Washington D.C. ... on January 26 at 10:30 a.m. EST at the Grand ...
(Date:1/23/2015)... Jan. 23, 2015  Pete Rose, baseball,s all-time hits leader, is ... pain reliever Myoflex, Ducere Pharma has announced. "Pete,s ... excited to have him on board with Myoflex," said Ducere ... a legendary player who is known across all generations. The ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... New Zealand, Aug. 24 Rex Bionics Ltd., the ... walk, announced formation of an International Advisory Board that ... Williams .  Also named to the new board were ... of Virginia, Charlottesville, Va., and Frank Gardner, the BBC,s ...
... Bulletin Board: SNDZ ), announced today that it ... key brokers and funds.  The purpose of these meetings will ... facilitate funding for Sunridge to execute its business plan for ... this project," states G. Richard Smith, CEO of Sunridge.  "We ...
Cached Medicine Technology:Award-Winning U.S. Talk Show Host Montel Williams Joins Rex Bionics New International Advisory Board 2
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... minority patients generally receive a lower quality of ... these disparities be reduced? A supplement to the ... Review, published by SAGE, thoroughly explores the effectiveness ... , The supplement features research from the Finding ...
... Inc. (OTC BB:,ALRX), a specialty pharmaceutical company dedicated ... inflammatory and infectious disease,today announced the retirement of ... unanimous resolution of the Board of Directors, certain,unsecured ... officers and third,party investors, including earned and unpaid ...
... 28 Cardiac Science,(Nasdaq: CSCX ), a ... has been named to Deloitte,s prestigious,Technology Fast 50 ... 50,fastest growing technology, media, telecommunications, and life sciences,companies ... LLP, one of the nation,s,leading professional services organizations. ...
... Small Bone Innovations,Inc. (SBi), a single-source provider of ... joint orthopedic market sector, announced today the,launch of ... further,augment its Elbow Management System, the company also ... proximal radius,fractures. The rHead Lateral Implant is ...
... that helps them appreciate another,s discomfort shuts down, study finds ... to switch off the part of their brain that helps ... turn on a brain area that controls emotions, according a ... have to inflict pain on patients while treating them, doctors ...
... Euro 39 Million - Aesthetic Therapies and Ambulant Urology Laser ... ... September 28 , http://www.biolitec.com - biolitec AG, Jena listed in ... increase the,revenues during the fiscal year ending June, 30 2007 by ...
Cached Medicine News:Health News:Cardiac Science Named to Deloitte's Technology Fast 50 for Washington State 2Health News:Cardiac Science Named to Deloitte's Technology Fast 50 for Washington State 3Health News:Cardiac Science Named to Deloitte's Technology Fast 50 for Washington State 4Health News:SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System 2Health News:SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System 3Health News:SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System 4Health News:Brain 'Switch' Helps Doctors Deal With Patients' Pain 2Health News:biolitec AG - Record Profit in FY 2006/07 With a Growth of 191% to Euro 6,7 Million 2
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
RM-1900 Dermatome developed for reconstructive plastic surgery with E-Type coupling. Dermatome with 50 mm cutting width....
... Model C Dermatome - reaching a new evolutionary ... forward to operate in the pulse mode, or ... the entire instrument and hose assembly is autoclavable ... in 2-, 3-, or 4-inch widths. Simply select ...
Medicine Products: